Edwards Lifesciences (NYSE:EW – Get Free Report) will be releasing its earnings results after the market closes on Thursday, October 24th. Analysts expect Edwards Lifesciences to post earnings of $0.67 per share for the quarter. Edwards Lifesciences has set its Q3 guidance at $0.67-0.71 EPS and its Q3 2024 guidance at 0.670-0.710 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the prior year, the business earned $0.66 EPS. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Edwards Lifesciences Trading Down 0.3 %
EW stock opened at $70.05 on Tuesday. The stock has a market cap of $42.21 billion, a price-to-earnings ratio of 30.19, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a fifty day moving average price of $67.90 and a two-hundred day moving average price of $78.93. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.
Analyst Ratings Changes
Get Our Latest Stock Analysis on EW
Insider Transactions at Edwards Lifesciences
In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,250 shares of company stock valued at $1,099,238. Corporate insiders own 1.29% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Best Stocks Under $5.00
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What Are Dividend Contenders? Investing in Dividend Contenders
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.